1-5 of 5
Michael C O'Dwyer, MD FRCPI, FRCPath
Close
Sort by
Journal Articles

A Single Centre Analysis of Spectra Optia Stem Cell Collection Data from Multiple Myeloma and Lymphoma Patients, with and without Plerixafor

Joy Buckley, M.Sc. B.Sc., Janusz Krawczyk, MD MRCP, Fionnuala Ni Chonchubhair, MSc, BSc., Nelly Besson, PhD, Margaret Tarpey, MSc. BSc., Margaret Murray, MD, F.R.C.Path., F.R.C.P.I. F.F.Path, M.R.C.P. (U.K.), Michael C O'Dwyer, MD FRCPI, FRCPath, Amjad Hayat, MBBS, MRCP, MRCPath, PhD
Journal: Blood
Blood (2014) 124 (21): 3848.
https://doi.org/10.1182/blood.V124.21.3848.3848
Published: 2014
Journal Articles

Increased Activity of the S Phase Kinase Cdc7 Is Associated with Poor Outcome in Diffuse Large B Cell Lymphoma (DLBCL).

Janusz Krawczyk, MB, Caoimhe Egan, MB, Michelle Mulvihill, MB, Mark Webber, MD, Laura Murillo, MD, Helen Ingoldsby, MD, Corrado Santocanale, PhD, Grace Callagy, MB, PhD, MRCPI, FRCPath, Michael C O'Dwyer, MD, FRCPI, FRCPath
Journal: Blood
Blood (2009) 114 (22): 1914.
https://doi.org/10.1182/blood.V114.22.1914.1914
Published: 2009
Journal Articles

MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia.

Ronan T. Swords, M.D., Kevin R. Kelly, MD, Peter G. Smith, PhD, James J. Gansey, Devalingam Mahalingam, M.D., Swaminathan Padmanabhan, MD, MBBS, Michael C. O'Dwyer, MD, FRCPI, FRCPath, Steffan T. Nawrocki, PhD, Francis J. Giles, MD, Jennifer S. Carew, Ph.D.
Journal: Blood
Blood (2009) 114 (22): 1021.
https://doi.org/10.1182/blood.V114.22.1021.1021
Published: 2009
Journal Articles

PHA767491, a Dual Cdc7/CDK9 Inhibitor, with Potential to Target Both Proliferation and Survival in CLL.

Alessandro Natoni, PhD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Alessia Montagnoli, PhD, Grace Callagy, MB, PhD, MRCPI, FRCPath, Afshin Samali, PhD, Corrado Santocanale, PhD, Michael C O'Dwyer, MD, FRCPI, FRCPath
Journal: Blood
Blood (2009) 114 (22): 2366.
https://doi.org/10.1182/blood.V114.22.2366.2366
Published: 2009
Journal Articles

Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.

Michael C O'Dwyer, MD, FRCPI, FRCPath, Emma Kent, Michael Parker, BSc, MSc, CStat, CMath, Ronan T. Swords, M.D., Frank Giles, MD, MB, FRCPI, FRCPath, Philipp le Coutre, MD, Swaminathan Padmanabhan, MD, MBBS, Brian Moulton, Ph.D, Mary Frances McMullin, Stephen Langabeer, PhD, Karine Egan, Ph.D, Eibhlin Conneally, MB, MRCP, MRCPath, PhD
Journal: Blood
Blood (2009) 114 (22): 3294.
https://doi.org/10.1182/blood.V114.22.3294.3294
Published: 2009